An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer
- 10 February 2007
- journal article
- retracted article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (5) , 517-525
- https://doi.org/10.1200/jco.2006.06.3743
Abstract
Purpose The purpose of this study was to develop an integrated genomic-based approach to personalized treatment of patients with advanced-stage ovarian cancer. We have used gene expression profiles to identify patients likely to be resistant to primary platinum-based chemotherapy and also to identify alternate targeted therapeutic options for patients with de novo platinum-resistant disease. Patients and Methods A gene expression model that predicts response to platinum-based therapy was developed using a training set of 83 advanced-stage serous ovarian cancers and tested on a 36-sample external validation set. In parallel, expression signatures that define the status of oncogenic signaling pathways were evaluated in 119 primary ovarian cancers and 12 ovarian cancer cell lines. In an effort to increase chemotherapy sensitivity, pathways shown to be activated in platinum-resistant cancers were subject to targeted therapy in ovarian cancer cell lines. Results Gene expression profiles identified patients wit...Keywords
This publication has 30 references indexed in Scilit:
- Sparse Statistical Modelling in Gene Expression GenomicsPublished by Cambridge University Press (CUP) ,2006
- Molecular profiling of platinum resistant ovarian cancerInternational Journal of Cancer, 2005
- Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 2005
- Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian CancersClinical Cancer Research, 2005
- Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarraysAmerican Journal of Obstetrics and Gynecology, 2004
- Gene Expression Patterns in Ovarian CarcinomasMolecular Biology of the Cell, 2003
- Exploration, normalization, and summaries of high density oligonucleotide array probe level dataBiostatistics, 2003
- Loss of Expression of the p16 Tumor Suppressor Gene Is More Frequent in Advanced Ovarian Cancers Lacking p53 MutationsGynecologic Oncology, 2001
- p21 (WAF1/CIP1) Protein Expression Is Associated with Prolonged Survival but Not with p53 Expression in Epithelial Ovarian CarcinomaGynecologic Oncology, 2000
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996